How far are we from an approved drug for nonalcoholic steatohepatitis?
Sign Up to like & getrecommendations! Published in 2023 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2023.2206953
Abstract: ABSTRACT Introduction Metabolic-associated fatty liver disease (MAFLD) previously known but still debatable, as nonalcoholic fatty liver disease (NAFLD) is one of the main causes of chronic liver disease and subsequent cirrhosis worldwide, accounting for around… read more here.
Keywords: disease; liver disease; mafld nafld; far approved ... See more keywords